Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Phanes Therapeutics

Request full access

A company focused on innovative drug discovery and early development in immuno-oncology and eye disease

San Diego, United StatesFounded 2016Biotech & Life Sciences

About Phanes Therapeutics

Phanes Therapeutics, Inc. operates as a clinical-stage biotechnology company with a sharp focus on oncology. Founded in July 2016 by Dr. Ming Wang, an industry veteran with extensive experience at global pharmaceutical giants like Johnson & Johnson, Amgen, and Pfizer, the company is headquartered in San Diego. Dr. Wang's background includes a Ph.D. in Biochemistry and an MBA, and he has a track record of leading drug discovery and development programs in metabolic diseases and oncology, which directly informs the company's strategic direction.

The company's business model centers on the discovery and development of novel biologic drugs to address significant unmet medical needs in cancer. Phanes Therapeutics generates value by advancing its proprietary pipeline through clinical trials, with a strategy that includes potential out-licensing, development collaborations, and strategic partnerships with larger pharmaceutical companies. This is evidenced by its clinical trial collaborations with major players like Merck, BeiGene, and Roche to evaluate its drug candidates in combination with established therapies.

Phanes has built its pipeline by leveraging three proprietary technology platforms for creating bispecific antibodies: PACbody®, for constructing stable, native IgG-like bispecific antibodies; SPECpair®, which allows for conventional, more efficient manufacturing processes; and ATACCbody®, designed to modulate antibody activity to minimize risks like cytokine release syndrome in solid tumor treatments. These platforms received registered trademarks from the U.S. Patent and Trademark Office in January 2024.

The company's clinical pipeline includes three main assets. PT199 (mavrostobart) is a monoclonal antibody targeting CD73 to counter the immunosuppressive tumor microenvironment and is being evaluated in the MORNINGSTAR Phase I/II study for advanced solid tumors. PT886 (spevatamig) is a first-in-class bispecific antibody targeting both Claudin 18.2 and CD47, developed to kill tumor cells via multiple immune pathways. It has received Orphan Drug and Fast Track designations from the FDA for pancreatic cancer and is being studied in the TWINPEAK trial. PT217 (peluntamig) is another first-in-class bispecific antibody targeting DLL3 and CD47 for cancers like small cell lung cancer (SCLC) and neuroendocrine tumors. It is also under evaluation in a Phase I/II trial known as SKYBRIDGE and has received both Orphan Drug and Fast Track designations.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2016
Headquarters
San Diego, United States
Employees
29
Open positions
1
Dealroom signal
74.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
OtherOther financing Jan 2024 $0 — Undisclosed ↗
SERIES B✓Equity / VC May 2021 $40M $160M Delos Capital · HSG · Volcanics Venture · Dyee Capital —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Phanes Therapeutics website traffic

Latest recorded traffic for Phanes Therapeutics is 3.2K monthly website visits, up 33.3% over the last three months. Phanes Therapeutics's team grew 16% over the past year.

Latest monthly visits3.2K 3-month web change+33.3% 1-year team growth+16%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Phanes Therapeutics in the San Diego ecosystem

Live from Dealroom

The Phanes Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Delos Capital
  • HSG
  • Volcanics Venture
  • Dyee Capital
  • Wen Zhou Fund

Other known investors1 additional known investor

  • Kaitai Capital
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Phanes Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Phanes Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.